Seelos Therapeutics (SEEL) News Today $1.39 -0.06 (-4.14%) (As of 12/29/2023 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineSeelos Therapeutics, Inc. Releases Letter to its Stockholdersfinance.yahoo.com - December 22 at 9:07 AM11 Most Promising Psychedelic Stocks According to Hedge Fundsfinance.yahoo.com - December 20 at 3:30 PMSeelos Therapeutics files for $250M mixed shelfmsn.com - December 18 at 8:02 PMSeelos Therapeutics (SEEL) Price Target Increased by 2900.00% to 122.40msn.com - December 16 at 3:27 PMInsider Spends US$100k Buying More Shares In Seelos Therapeuticsfinance.yahoo.com - December 4 at 8:19 AMInsider Buying: CFO Michael Golembiewski Acquires 83,000 Shares of Seelos Therapeutics Inc (SEEL)finance.yahoo.com - December 2 at 8:16 AMSeelos Therapeutics Announces Closing of Public Offeringfinance.yahoo.com - December 1 at 8:21 PMThinking about buying stock in Neximmune, ShiftPixy, Ampio Pharmaceuticals, Seelos Therapeutics, or Nio Inc?benzinga.com - December 1 at 10:20 AMThinking about buying stock in RedHill Biopharma, Mynaric, Energy Transfer LP, Seelos Therapeutics, or Petco Health and Wellness?benzinga.com - November 29 at 10:25 AMSeelos Therapeutics Shares Slide Premarket After Public Offeringmarketwatch.com - November 29 at 10:25 AMWhy Is Seelos Therapeutics (SEEL) Stock Down 42% Today?investorplace.com - November 29 at 10:02 AMSeelos Therapeutics Announces Pricing Of $5.55 Mln Public Offering; Stock Dropsmarkets.businessinsider.com - November 28 at 11:37 PMSeelos Therapeutics commences a public offering of its sharesmsn.com - November 28 at 6:37 PMSeelos Therapeutics Announces Proposed Public Offeringfinance.yahoo.com - November 28 at 6:37 PMSeelos stock falls 23% following 1-for-30 reverse splitmsn.com - November 28 at 1:36 PMSeelos Therapeutics, Iterum Therapeutics among healthcare moversmsn.com - November 28 at 1:36 PMmarketbeat.com - November 28 at 6:05 AMDefense Dept. Funds Ketamine Study For PTSD Treatment In 600 Service Members & Veteransmsn.com - November 27 at 5:33 PMSeelos' SLS-002 To Be Included In DOD's Trial To Evaluate Potential Treatments For PTSDmarkets.businessinsider.com - November 27 at 9:08 AMSeelos Therapeutics Announces the Selection of SLS-002 (intranasal racemic ketamine) for Inclusion in the U.S. Department of Defense's Adaptive Platform Trial to Evaluate Potential Treatments for Post-Traumatic Stress Disorder (PTSD)finance.yahoo.com - November 27 at 9:08 AMSeelos to Implement 1-for-30 Reverse Stock Splitmarketwatch.com - November 24 at 1:42 PMWhy Seelos Therapeutics Shares Are Diving Todaybenzinga.com - November 24 at 1:42 PMSeelos Therapeutics Announces 1-for-30 Reverse Stock Splitfinance.yahoo.com - November 24 at 1:42 PMDole (DOLE) Q3 Earnings Top Estimatesmsn.com - November 16 at 12:14 PMSeelos Therapeutics (SEEL) Price Target Increased by 60.00% to 4.08msn.com - November 1 at 2:30 PMSeelos Therapeutics to Present a Poster on SLS-005 in Alzheimer's Disease at Neuroscience 2023finance.yahoo.com - October 27 at 12:45 PMSeelos Therapeutics Retains Canaccord Genuity in Connection with Review of Potential Partnerships and Collaborationsfinance.yahoo.com - October 17 at 10:22 AMEmpery Alleges Critical Clinical Trial Misrepresentations by Seelos Therapeuticsfinance.yahoo.com - October 10 at 2:25 PMSeelos Therapeutics' Aggressive Alzheimer's Hopeful Candidate Shows Encouraging Preclinical Activitymsn.com - September 27 at 11:01 PMSeelos Announces Encouraging Data From Study Of SLS-005 In Preclinical Model Of Alzheimer's Diseasemarkets.businessinsider.com - September 27 at 12:59 PMSeelos Therapeutics Announces Encouraging Data from an In Vivo Study of SLS-005 in an Aggressive Preclinical Model of Alzheimer's Diseasefinance.yahoo.com - September 27 at 12:59 PMGuggenheim Downgrades Seelos Therapeutics (SEEL)msn.com - September 23 at 7:50 AMSeelos Therapeutics Hits Another New Low After Stock Sale >SEELmarketwatch.com - September 22 at 7:52 PMBenchmark Maintains Seelos Therapeutics (SEEL) Speculative Buy Recommendationnasdaq.com - September 22 at 7:52 PMWhere Seelos Therapeutics Stands With Analystsmarkets.businessinsider.com - September 22 at 2:52 PMWhy Is Seelos Therapeutics (SEEL) Stock Down 25% Today?investorplace.com - September 21 at 1:02 PMSeelos Therapeutics Shares Slide Premarket on SLS-002 Study Shortfall >SEELmarketwatch.com - September 20 at 7:43 PMWhy Is Depression Focused Seelos Therapeutics Stock Plunging Today?msn.com - September 20 at 2:43 PMSeelos Therapeutics Shares Plumb New Depths on Study Shortfall >SEELmarketwatch.com - September 20 at 2:43 PMUS Futures Rise Modestly Pre-Bell as Investors Await Fed Rate Decisionmsn.com - September 20 at 9:42 AMSeelos Therapeutics’ stock slides 36% after trial of treatment for suicidal ideation has too few patients to meet endpointmsn.com - September 20 at 9:42 AMSeelos Therapeutics: SLS-002 Phase II Study Fails To Meet Primary Endpoint On Limited Sample Sizemarkets.businessinsider.com - September 20 at 9:42 AMSeelos tumbles 66% as depression drug fails after it recruits too few patientsproactiveinvestors.com - September 20 at 9:42 AMSeelos Therapeutics Announces Top Line Results from SLS-002 Phase II Study in Adults with Major Depressive Disorder at Imminent Risk of Suicidefinance.yahoo.com - September 20 at 9:42 AM7 Biotech Stocks to Sell in September Before They Crash & Burnfinance.yahoo.com - September 14 at 10:37 AM4 Analysts Have This to Say About Seelos Therapeuticsmarkets.businessinsider.com - August 22 at 6:27 PMMAI Capital Management Has $641,000 Stock Holdings in Seelos Therapeutics, Inc. (NASDAQ:SEEL)marketbeat.com - August 22 at 6:41 AMMirae Asset Global Investments Co. Ltd. Boosts Stock Holdings in Seelos Therapeutics, Inc. (NASDAQ:SEEL)marketbeat.com - August 18 at 4:24 AMCantor Fitzgerald Reiterates Seelos Therapeutics (SEEL) Overweight Recommendationmsn.com - August 16 at 2:25 AMSeelos Therapeutics Provides Second Quarter 2023 Clinical Updatefinance.yahoo.com - August 14 at 6:03 PM Get Seelos Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SEEL and its competitors with MarketBeat's FREE daily newsletter. Email Address SEEL Media Mentions By Week SEEL Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SEEL News Sentiment▼1.870.84▲Average Medical News Sentiment SEEL News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SEEL Articles This Week▼12▲SEEL Articles Average Week Get Seelos Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SEEL and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: IMNN News Today ABVC News Today GOVX News Today ERNA News Today JAGX News Today ASLN News Today BNTC News Today NRSN News Today PBLA News Today ARAV News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat Originals This page (NASDAQ:SEEL) was last updated on 12/31/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Seelos Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.